Neoadjuvant multidrug chemotherapy including High-Dose Methotrexate modifies VEGF expression in Osteosarcoma: an immunohistochemical analysis

[1]  V. Sreenivas,et al.  VEGF expression as a prognostic marker in osteosarcoma , 2009, Pediatric blood & cancer.

[2]  T. Yamashita,et al.  The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. , 2009, The Journal of bone and joint surgery. British volume.

[3]  B. Zafirova-Ivanovska,et al.  Treatment of non-metastatic high-grade osteosarcoma (study of 30 cases treated with Scandinavian osteosarcoma protocol XIV and surgery). , 2008, Prilozi.

[4]  Zhixiong Lin,et al.  Prognostic Significance of αV Integrin and VEGF in Osteosarcoma after Chemotherapy , 2008, Oncology Research and Treatment.

[5]  J. Healey,et al.  Hypoxia Markers in Human Osteosarcoma: An Exploratory Study , 2008, Clinical orthopaedics and related research.

[6]  E. Kleinerman,et al.  The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice , 2008, British Journal of Cancer.

[7]  G. Demetri,et al.  Markers of angiogenesis and clinical features in patients with sarcoma , 2007, Cancer.

[8]  B. Seddon,et al.  Management of osteosarcoma , 2006, Current treatment options in oncology.

[9]  E. Rossi,et al.  Diagnostic Relevance of the Immunohistochemical Detection of Growth Factors in Benign and Malignant Cartilaginous Tumors , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[10]  R. Grimer,et al.  Vascular Endothelial Growth Factor Expression in Osteosarcoma , 2006, Clinical orthopaedics and related research.

[11]  Y. Iwamoto,et al.  CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis , 2006, Modern Pathology.

[12]  E. T. Ek,et al.  Outcome of patients with osteosarcoma over 40 years of age: Is angiogenesis a marker of survival? , 2006, International seminars in surgical oncology : ISSO.

[13]  A. Pappo.  Pediatric Bone and Soft Tissue Sarcomas , 2006 .

[14]  M. Kreuter,et al.  Prognostic relevance of increased angiogenesis in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Yamashita,et al.  Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. , 2004, The Journal of bone and joint surgery. British volume.

[16]  T. Yamashita,et al.  Postoperative Progression of Pulmonary Metastasis in Osteosarcoma , 2003, Clinical orthopaedics and related research.

[17]  T. Yamashita,et al.  Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma , 2002, British Journal of Cancer.

[18]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Ferrari,et al.  Histologic Response of High-Grade Nonmetastatic Osteosarcoma of the Extremity to Chemotherapy , 2001, Clinical orthopaedics and related research.

[20]  G. Ayala,et al.  Microvasculature and VEGF expression in cartilaginous tumors. , 2000, Human pathology.

[21]  F. Higashino,et al.  Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Y. Oshika,et al.  Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. , 1999, European journal of cancer.

[23]  M. Mizumoto,et al.  Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. , 1998, British Journal of Cancer.

[24]  井上 公俊.  Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma , 1997 .

[25]  T. Wada,et al.  A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. , 1996, Oncology.

[26]  T. Sawada,et al.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma , 1996, Cancer.

[27]  W. Enneking.  A system of staging musculoskeletal neoplasms. , 1988, Instructional course lectures.

[28]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[29]  W. Enneking.  A system of staging musculoskeletal neoplasms. , 1986, Clinical orthopaedics and related research.

[30]  N. Jaffe,et al.  Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor , 1985, Cancer.